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Identity 
Note: The nosology of aCML is controversial. The 
FAB classification includes aCML in the group of 
chronic myeloid leukemias. The WHO classification 
has classified aCML in the group of 
myelodysplastic/myeloproliferative diseases. 
Clinics and pathology 
Disease 
aCML is a chronic myeloproliferative disorder with a 
clinical and hematological picture similar to chronic 
myelogenous leukemia (CML) but lacking Philadelphia 
chromosome and BCR - ABL or PDGFRBeta 
rearangements. Atypical CML is characterized by the 
combination of: 10-20% of immature granulocytes; 
marked granulocytic dysplasia and both less than 2% of 
basophils and less than 10% of monocytes. 
Phenotype/cell stem origin 
Presumably a multipotential stem cell. 
Epidemiology 
ACML is a rare disorder of old adults. No 
predominance of sex. The incidence is not established. 
Clinics 
Anemic syndrome. Splenomegaly. Malaise. 
Cytology 
Peripheral blood: Leukocytosis with a high count of 
immature granulocytes. By definition monocytes  
are less than 10% and basophils less than 2%. Anemia 
is more frequent than thrombocytopenia.  
Bone marow: Hypercellular with myelodysplastic 
features of the three series, most marked in 
granulocytic lineage. Blast cell infiltration ranges from 
0% to 10%. 
Treatment 
Hydroxyurea is indicated, although not curative, in old 
patients. Complete remission may be achieved after 
chemotherapy based on anthracyclin and citarabine (an 
acute myeloblastic leukemia therapy schedule). 
Allogeneic bone marrow transplantation is the only 
curative therapy for those patients who are eligible. 
Some cases may achieve a complete hematological 
response after interferon therapy. 
Prognosis 
The median survival is about 24 months with standart 




By definition aCML cases lack in Philadelphia 
chromosome. Overall 50-65% of patients show 
cytogenetic abnormalities. The most frequent is +8 
(25%). Other changes such as -7 and del(12p) have also 
been recurrently observed. Other abnormalities are: 
idic(Xq); del(5q); t(6;8)(p23;q22); -9; del(11q); 
del(12q); del(15q); del(17p); t(17;20) and add(21q). No 
specific cytogenetic changes have been associated with 
aCML. Rearrangements of PDGFRb gene, located at 
5q33 have been described a t(5;10)(q33;q22) have been 
described in several patients. 
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Genes involved and proteins 
Note 
The mechanisms of oncogenesis in aCML remains to 
be elucidated. In the last years some cases displaying 
rearrangement PDGFRb have been reported. Most of 
these cases showed PDGFRb/ETV6 fusion, but also a 
fusion with H4 gene (located at 10q22), have been 
described. A total of 8 different genes have been found 
fused to PDGFRb gene. The diagnosis of these 
cytogenetic abnormalities are critical since most these 
cases could achieve a complete cytogenetic response 
with imatinib therapy. The JAK2V617F activating 
tyrosine kinase mutation is unfrequent in aCML. 
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